Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash & Equivalents (2020 - 2025)

Ovid Therapeutics' Cash & Equivalents history spans 6 years, with the latest figure at $13.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 48.98% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $13.2 million, down 48.98%, while the annual FY2025 figure was $13.2 million, 48.98% down from the prior year.
  • Cash & Equivalents reached $13.2 million in Q4 2025 per OVID's latest filing, down from $20.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $233.1 million in Q1 2021 to a low of $13.2 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $78.3 million, with a median of $49.3 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 752.52% in 2021, then tumbled 77.63% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $187.8 million in 2021, then crashed by 77.63% to $42.0 million in 2022, then tumbled by 35.64% to $27.0 million in 2023, then fell by 4.67% to $25.8 million in 2024, then crashed by 48.98% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Cash & Equivalents are $13.2 million (Q4 2025), $20.6 million (Q3 2025), and $20.7 million (Q2 2025).